The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

ABPI has issued its response to the recently published report and recommendations from the International Trade Committee on the impacts of COVID-19 on international trade.

Industry Responds to International Trade Committee’s Recommendations

The companies will combine Intravacc’s OMV delivery platform with S-proteins with Celonic’s CHOvolution mammalian cell expression system to produce B and T-cell responses against SARS-CoV-2.

Intravacc and Celonic Partner for COVID-19 Vaccine Development

The UK government is committing a further £100 million (US $127 million) to ensure that there is capability to manufacture a successful COVID-19 vaccine at scale in the UK.

UK Government Provides Cash Boost for COVID-19 Vaccine Manufacture

The European Medicines Agency has set up an infrastructure to support real-world monitoring of the efficacy and safety of COVID-19 vaccines and treatments.

EMA Sets Up Infrastructure to Support Real-World Monitoring of COVID-19 Vaccines

An LIMS system enables a COVID-19 testing center for employees at their workplace.

LabVantage COVID-19 LIMS Solution Launched for Workplace Health and Safety

Pending approval of the Pfizer and BioNTech mRNA-based vaccine candidate against SARS-COV-2, the companies will supply the US government with an initial 100 million doses. 

Pfizer and BioNTech Sign Supply Agreement with US Government for Vaccine Candidate

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Should therapies and vaccines be cheap or free in a pandemic and would that really dry up innovation? 

Drug Pricing Back in the Spotlight

The project will focus on providing a faster route to clinical studies for AstraZeneca’s potential COVID-19 vaccine, AZD1222.

AstraZeneca and IQVIA Partner on Potential COVID-19 Vaccine

The UK government has secured early access to 90 million COVID-19 vaccine doses from the BioNTech/Pfizer alliance and Valneva.

UK Government Secures Early Access to Millions of COVID-19 Vaccine Doses

GSK and CureVac will collaborate on mRNA-based vaccines and mAbs. Separately, the EIB and others provided CureVac with financing for development of its CVnCoV vaccine candidate and expansion of manufacturing.

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success